Insider Transactions in Q1 2021 at Derm Tech, Inc. (DMTK)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 29
2021
|
John Dobak Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
29,195
+4.91%
|
-
|
|
Mar 29
2021
|
Claudia Ibarra Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,985
+4.72%
|
-
|
|
Mar 29
2021
|
Burkhard Jansen Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,897
+5.45%
|
-
|
|
Mar 29
2021
|
Kevin M Sun Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,020
+4.79%
|
-
|
|
Mar 29
2021
|
Todd Michael Wood Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,162
+4.51%
|
-
|
|
Mar 18
2021
|
John Dobak Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,150
-1.32%
|
$378,950
$53.35 P/Share
|
|
Mar 08
2021
|
John Dobak Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
780
-0.14%
|
$39,000
$50.04 P/Share
|
|
Mar 08
2021
|
Claudia Ibarra Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,431
-2.07%
|
$121,550
$50.04 P/Share
|
|
Mar 08
2021
|
Kevin M Sun Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,886
-1.87%
|
$144,300
$50.04 P/Share
|
|
Mar 08
2021
|
Todd Michael Wood Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
417
-0.25%
|
$20,850
$50.04 P/Share
|
|
Jan 26
2021
|
Rtw Investments, LP > 10% Shareholder |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
31,450
+1.0%
|
$283,050
$9.54 P/Share
|
|
Jan 26
2021
|
Burkhard Jansen Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+5.95%
|
$30,000
$6.94 P/Share
|
|
Jan 11
2021
|
Matthew L. Posard Director |
BUY
Open market or private purchase
|
Direct |
33,898
+28.07%
|
$983,042
$29.5 P/Share
|
|
Jan 07
2021
|
Rtw Investments, LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
200,000
+6.08%
|
$5,800,000
$29.5 P/Share
|
|
Jan 05
2021
|
Ramin Akhavan General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
36,250
+31.06%
|
-
|